<p>Chuck Ryan from MSKCC joins to talk about various aspects of AR inhibition in prostate cancer and relative benefits and risks.</p>

Chuck Ryan from MSKCC joins to talk about various aspects of AR inhibition in prostate cancer and relative benefits and risks.

Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer

Broadcasting the latest developments in GU cancer

Hosted by Brian Rini and Tom Powles 

Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Medicine

Health & Fitness

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Share Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer

Sign up to save your podcasts

Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer

Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer

More shows like The Uromigos

JAMA Editors' Summary

NEJM This Week

AFP: American Family Physician Podcast

JAMA Clinical Reviews

Prostate Cancer Update

ASCO Daily News

White Coat Investor Podcast

The Curbsiders Internal Medicine Podcast

The Peter Attia Drive

Annals On Call Podcast

The Clinical Problem Solvers

GU Cast | Urology Podcast

BioCentury This Week

Two Onc Docs

The View on GU | with Lalani and Wallis